Summary
In this article, we consider four aspects of the regulatory standing of status epilepticus and the difficulties these raise in relation to trials and licensing. These formed the basis of a discussion held at the 6th London-Innsbruck Colloquium on Status Epilepticus, held on April 6, 2017.
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| IS STATUS EPILEPTICUS A CONDITION (A DISEASE ENTITY) IN ITS OWN RIGHT, OR SIMPLY A SEVERE VARIANT OF A SEIZURE?
A recent indication by the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMA) suggested that they would turn down an application for orphan drug status for a new compound designed to be used in the treatment of status epilepticus, on the basis that "status epilepticus" is just a severe manifestation or complication of epilepsy and therefore is not a disease or condition in its own right. This raises interesting questions of principle and also has profound practical implications for drug licensing in the field of status epilepticus.
| What is a disease entity?
Defining a disease is not a simple matter and depends a great deal on the perspective taken. The medical perspective is very different from the societal perspective and there are geographic, social, cultural, and historical influences on "what is a disease." Two examples are osteoporosis, which switched from being an unavoidable part of aging to a pathology in 1964, and also homosexuality, which has traveled in the opposite direction, considered to be an endocrine disorder requiring hormonal treatment right up to the middle of the 20th century. 1 From a medical perspective, the differentiation of disease from a symptom often depends on the former having a defined cause, which results in the latter. In the case of epilepsy, though, establishing a cause is not necessarily an easy matter, and the complexities are discussed elsewhere. 2, 3 Definition in mental disease (and including epilepsies, as they are manifestations of disturbance of normal brain activity) is a particularly thorny issue. Indeed, some have doubted the very existence of "mental disease," considering these to be mainly, or at least to an extent, social constructs. 1 Much has been written about the crude commercialism of symptoms, and criticisms have been leveled against the pharmaceutical industry for "medicalizing" human behavior by creating new diseases and then supplying drugs to treat the new disease (examples are Ritalin for attention deficit disorder or Viagra for female sexual dysfunction 1 ). There can be no doubt that the effects of having epilepsy can be hugely influenced by the cultural norms of the time and by geographical location; and any satisfactory definition of epilepsy must take this into account. Temkin 4 was surely correct when he said that epilepsy was "a tangle of human history and natural history." These points are discussed further elsewhere.
Sometimes distinctions are drawn between a disease, disorder, and condition. It is true that these have different connotations in societal settings but from the medical perspective are surely essentially the same thing.
| Current definitions

| A condition
The EMA defines a "condition" as: any deviation(s) from the normal structure or function of the body, as manifested by a characteristic set of signs and symptoms (typically a recognized distinct disease or a syndrome). It is worth noting too that Orphanet, which EMA regulation often relies upon in the field of rare diseases, does not provide any definition of a "condition," but nevertheless does produce a list of rare conditions. Status epilepticus is not mentioned on this list but does list NORSE (New Onset Refractory Status Epilepticus) as a condition. This too seems anomalous, as NORSE is surely only a form of status epilepticus in which no cause has been found. This makes no sense.
| Epilepsy
The International League Against Epilepsy (ILAE) definition of epilepsy is as follows: Epilepsy is a disease of the brain defined by any of the following conditions: (1) At least 2 unprovoked (or reflex) seizures occurring >24 hours apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after 2 unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy syndrome. In our opinion, a definition that focuses on whether seizures will recur does not get close to the essence of epilepsy (for discussion of current and past ILAE definitions see Shorvon 5 ).
| An epileptic seizure
Defining an "epileptic seizure" is easier than defining epilepsy, for a seizure is a neurobiological event for which the mechanisms are at least partially understood. 
| Status epilepticus
The ILAE-approved definition is the following: A condition in which the mechanisms of seizure termination fail leading to abnormally prolonged and self-perpetuating seizures (at time point t1). It is a condition that can have long-term consequences (after time point t2), including neuronal death and neuronal injury. The COMP is responsible for reviewing applications for orphan designation. To qualify for orphan designation, a medicine must meet a number of criteria:
• It must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating;
• The prevalence of the condition in the EU must not be more than 5 in 10 000 or it must be unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development;
• No satisfactory method of diagnosis, prevention, or treatment of the condition concerned can be authorized, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.
(Bold text is as used by the COMP). Status epilepticus meets all these criteria (of these there is no argument), but the question arises as to whether it is "a condition."
| Why should status epilepticus not be considered a condition?
We can say that there is compelling evidence to regard status epilepticus as a condition, which deserves emergency treatments in its own right. The arguments in favor of considering status epilepticus as a "condition" and, not just a severe epileptic seizure, include:
1. A fundamental property of a seizures is its transience, and this is not the case, by definition, in status epilepticus. 2. The clinical features of epilepsy are quite different. In super-refractory status epilepticus, the patient is lying in coma without any of the conventional clinical manifestations of a "seizure." 5. The physiology is also different. Status epilepticus is characterized by a failure of inhibitory mechanisms, and notably failure of γ-aminobutyric acid (GABA) ergic control. There is internalization of GABA receptors at synaptic membranes and also increase in the density of glutamatergic receptors and increased expression of excitatory glutamatergic N-methyl-Daspartate (NMDA) receptors. There are also changes in ionic environment, protein expression, second messengers, and so on. 6. The pathology is also completely different, with excitotoxic damage to the hippocampus, several thalamic nuclei, and areas of cortex, which simply do not occur in epilepsy. 16 7. The etiology differs in range and extent, and status epilepticus develops out of the blue in at least 50% of cases without any relationship to epilepsy. [17] [18] [19] 8. The accepted classifications of seizures and epilepsies are quite different status epilepticus. The major divisions of status are into convulsive and nonconvulsive forms. 6 9. The treatment of status epilepticus and ordinary epilepsy is completely different, with the former including the administration of intravenous antiepileptic drugs (AEDs), and also anesthetics and hypothermia, and immunologic and physical therapies. [20] [21] [22] 10. The clinical settings are completely different, with refractory and super-refractory status epilepticus being managed in intensive care units or emergency departments. 23 11. The prognosis and outcome of the 2 conditions are quite different, with status epilepticus having a 20%-40% mortality rate and 30% rate of neurologic deficits and consequences including epilepsy. 19 12. In terms of the way the condition is discussed in academic medical circles in experiments, in books, papers, websites, and congresses they are obviously distinct. 16, 24 The counter argument, that status epilepticus is not a distinct condition, can only really be made in early status epilepticus, and to the fact that status can evolve out of an ordinary epileptic seizure. Particularly, when status epilepticus is defined as a seizure of 5 or so minutes in duration, this blurs the distinction between a seizure and status epilepticus-and it is difficult to argue that at 5 minutes there is any clinical or pathologic difference between the 2 conditions, or indeed any treatment difference, but the likelihood that this seizure will not stop spontaneously. An analogy here of course may be the difference between angina and myocardial infarction, which are clearly distinct conditions, and in our view to deny defining a condition simply because it evolves from another makes little sense. Nevertheless, it may be that it would be a first step from the regulatory point of view to define refractory and superrefractory status epilepticus independently of early status epilepticus.
This topic was the subject of a lecture and an open discussion session with the delegates at the 6th LondonInnsbruck Colloquium on Status Epilepticus and Acute Seizures on April 6, 2017. A paper ballot was conducted at the end of this discussion, on the following two:
•
• (if answer is no to the above) Should Super-Refractory Status Epilepticus be considered as a disease entity for regulatory purposes? Over 80% voted in favor.
| CONSIDERATIONS IN STUDIES OF TREATMENT OF STATUS EPILEPTICUS
There are a number of issues that require consideration when designing, or conducting, trials of treatment in status epilepticus:
The function of treatment
In general terms, none of the antiepileptic drugs (AEDs) used in status epilepticus are designed to treat the cause, nor do they modify the course or prevent epilepsy developing after status epilepticus, They are symptomatic in its classical meaning. They "only" suppress the seizure generation; hence, they are not antiepileptic therapies sensu stricto. 25 Indeed, there was a move to rename AEDs to antiseizure drugs, because this would better reflect the symptomatic nature of the treatment. 26 2. The license for currently used AEDs in status epilepticus
The AEDs that are used in status epilepticus are approved for use in epilepsy on the basis that they prevent the occurrence of seizures in patients with chronic or new-onset epilepsy. In status epilepticus, a drug is needed to interrupt seizures, and this is a quite different situation and one in which the current design of AED regulatory studies does not allow any conclusions to be reached.
In status epilepticus, intravenous or other parenteral preparations are widely used, and it should be noted:
• None of the currently available parenteral preparations of AEDs, with the notable exception of buccal midazolam and rectal diazepam, which are currently licensed for the treatment of "acute repetitive seizures," have demonstrated efficacy in status epilepticus in any welldesigned clinical trials.
• The labels for phenobarbital and phenytoin have been granted by so-called "grandmother clauses," and no trials to modern standards were carried out.
• The license for the intravenous formulation of newer drugs is for their "use in patients, who are temporarily unable to swallow." For this purpose, bioequivalence studies are all that is required, and have been carried out (eg, for drugs such as levetiracetam, lacosamide, carbamazepine, and brivaracetam) usually in only small numbers of healthy adults.
• Other drugs used in status epilepticus, such as propofol, thiopental/pentobarbital, or ketamine are licensed for anesthetic purposes, but not for status epilepticus.
Off-label use
Most prescribing in status epilepticus is "off-label." In a recent survey from Austria, Germany, and Switzerland on 1049 patients with status epilepticus, 42% received offlabel therapies as the first-line medication: 15% intravenous levetiracetam and 32% intravenous midazolam, either alone or in combinations with other AEDs. 27 From a global audit on refractory and super-refractory status epilepticus we are informed that only a minority is treated within the label. 23 In addition, current clinical treatment guidelines recommend off-label therapies as the first-line treatment (eg, 28,29)
The fact that "off-label" treatment in status epilepticus is the rule and not the exception, is unsatisfactory for doctors for medicolegal reasons, and also for patients when potentially effective therapies are withheld because of the lack of regulatory approval.
Treating the cause
Some (non-AED) treatment in super-refractory stage of status epilepticus, such as immune therapies, is directed against the pathologic cause. The drug developmental pathway and the clinical outcome measures for licensing trials of these drugs are very different from those of drugs suppressing seizures.
Informed consent
Many if not most patients will be unable to give informed consent, and this poses legal and ethical obstacles that have to be addressed appropriately by measures, such as deferred informed consent.
Comparator drugs
There is also the question of the best comparator drug. Placebo-controlled trials in the early stages are likely to be considered unethical, since we know we have effective therapies (benzodiazepines) and to test against best medical practice in the later stages introduces a lot of variability into a trial with effects on sample size and the risk of bias. Most of the drugs that could be used as active comparators in the established or refractory stages are in fact also off label.
The lack of attraction of status epilepticus to industry
Finally, there is the small market argument from industry. Cases of status are rare, and the mortality is high. Many in the pharmaceutical industry feel that investments in trials are not economical, and it is for this reason that status epilepticus needs to be recognized as an orphan disease, the regulatory requirements for which are relatively facilitatory when compared to the regulations for drugs in more common disorders.
| TRIALS OF TREATMENT IN STATUS EPILEPTICUS
During recent years, several high-class randomized controlled trials have been performed by academic groups, such the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART). 30 Despite its conservative noninferior- This multicenter study uses a Bayesian adaptive design. Up to 795 patients will be randomized initially 1:1:1, and response-adaptive randomization will occur after 300 patients have been recruited. The study recruited ahead of schedule and the first result can be expected by the end of 2018. Of note, academic institutions have sponsored both aforementioned trials but not the pharma industry. SAGE pharmaceutical did sponsor the only well-designed randomized controlled study in the stage of super-refractory status epilepticus. This was of brexanolone, an intravenous formulation of the neurosteroid allopregnanolone, but the study failed to demonstrate effectiveness when SHORVON AND TRINKA | 131 compared to placebo, and in the opinion of many was a false-negative result due to the considerable methodologic hurdles of performing studies at the stage of super-refractory status epilepticus.
| OPPORTUNITIES FOR REGULATORY TRIALS
Status epilepticus is a condition where we need more and better informative trials, and recent experience has shown that it is possible to perform high-class trials to inform clinicians what the best treatment in each treatment stage of status epilepticus, although these studies are difficult (Figure 1 ). There are a number of issues that deserve further consideration.
1. For patients with preexisting epilepsy, one can assume, that a drug, which is efficacious in chronic treatment of bilateral tonic-clonic seizures lasting less than 5 minutes (or the respective t1 in other seizure types), is also efficacious when a seizure lasts 6 minutes or more (the "extrapolation argument"). We suggest that supportive data for licensing in epilepsy patients could come from extrapolation of the phase III licensing trials for chronic treatment, after testing for homogeneity of cause and age of the included population. Additional safety and bioequivalence data would be all that would then be needed to support the decision for approval in this setting. 2. In the early and established stage of status epilepticus, there are several high-class randomized controlled trials comparing various benzodiazepines. In our view, it would be reasonable to assume exchangeability of the treatment effect across all included trials, 34 allowing network meta-analysis with indirect comparisons to be made. 35 Such comparisons would be contingent on a common comparator (also known as "adjusted indirect comparison" 36 "common reference-based indirect comparison" 33 ) , and this represents a useful tool to provide information on relative efficacy of competing interventions where data from direct comparisons are not available 35 ( Figure 2 and there is some good evidence that blinded and unblinded RCTs usually point in the same direction, differing only in the size of the effect. 44 Safety data could be derived from well-designed observational trials, in which the necessary data quality and the study design are defined beforehand. 45 The ESETT study is a milestone in trial design, and the data will inform clinicians about the best available treatment in established status. The position of the regulators is unclear, where there is no difference in the treatment arms. As newer intravenous treatments are already available (such as brivaracetam and lacosamide) an ESETT II could be needed to address their effectiveness, but it is unlikely that industry will invest in such a study unless there is a clearly defined regulatory pathway for SE. 5. In refractory status epilepticus, where first-and secondline therapies failed, and the patient is under anesthesia, the situation is more complicated and clear clinical end points are difficult to define. Again, EEG surrogate measure and safety data in critically ill patients could serve as a starting point for a licensing trial with a clinical end point.
| CONCLUSION
There is wide consensus in the medical community that status epilepticus is a distinct condition and not just a different type of a seizure. The current situation that most of the patients are treated with off-label medication is not only unsatisfactory for the doctors but brings also some risks for the patients. There is a clear need for more high-quality trials at different stages of status epilepticus to better inform the clinicians about the appropriate choice of therapies for their patients. Clear regulatory pathways are needed to attract academia, research institutions, and industry to bring new, more effective drugs on the market for this life-threatening condition in the future.
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